Enable JavaScript to ensure website accessibility
Precipio Announces Shareholder Update Call On Commercial Progress

Conference call to be held Thursday October 10th at 5:00PM EST NEW HAVEN, CT, (October [...]

Clinical Validations For IV-Cell™ And HemeScreen™ Completed

Orders expected from several major labs both domestically and internationally NEW HAVEN, CT, (September 26th, [...]

Precipio And University Of Pennsylvania Enter Into Joint Collaboration Agreement For Pathology Diagnostics

First cases already diagnosed and reported by Penn expert pathologists NEW HAVEN, CT, (September 5th, [...]

Precipio Pathology Sales Metrics Demonstrate Continuous Improvement In Q2 2019

Three key metrics indicate growth over prior Quarter and same Quarter of 2018 NEW HAVEN, [...]

Precipio Announces Q2-2019 Corporate Update Call For Shareholders

Conference Call to be held on Wednesday, August 21st, 2019 at 5:00 PM EST NEW [...]

Global Expansion Efforts Begin Yielding Results

Asia is the first Key Geographic Focal Point NEW HAVEN, CT, (July 22nd, 2019) – Specialty [...]

Precipio And H3 Biomedicine Sign Second Development Agreement

Companies to create a panel amplifying targeted regions of key cancer genes NEW HAVEN, CT, [...]

Precipio CEO Provides Update Letter To Shareholders

NEW HAVEN, CT, (June 17th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides an update to [...]

Precipio Signs Exclusive Manufacturing Agreement For IV-Cell™

NEW HAVEN, CT, (June 4th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has [...]

Precipio Pathology Sales Performance Metrics Demonstrate Substantial Improvement In Q1-2019

Three key metrics are leading indicators of continuous revenue growth NEW HAVEN, CT, (May 30th, [...]